Cancer Survivors in the United States: Prevalence across the Survivorship Trajectory and Implications for Care

By Janet S. de Moor, A. Mariotto, Carla Parry, C. Alfano, Lynne S. Padgett, E. Kent, L. Forsythe, S. Scoppa, Mark Hachey, Julia H. Rowland. Cancer Epidemiology, Biomarkers and Prevention, 2013

637 citations recorded by the source corpus.

Subfields: Oncology, Pediatrics, Perinatology and Child Health, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/c2cbc6981bfb3aeacdc3dd9f26f3ba72a06db068

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Julia H. Rowland
2. A. Mariotto

Citations in the corpus

• Mechanisms of Chemotherapy-Induced Peripheral Neuropathy (2019, neutral): “7 million in 2012 to 18 million, by 2022 [2].”
• Anticipating the ‘Silver Tsunami’: Prevalence Trajectories and Co-Morbidity Burden Among Older Cancer Survivors in the United States (2016, background): “Currently, an estimated 64% of all survivors have lived 5 years beyond diagnosis and 40% have lived 10 years beyond diagnosis (3, 10).”
• The physics of proton therapy (2015, background): “Presently, about 3% of the US population are cancer survivors, corresponding to 11 million people, a figure projected to grow to 18 million by 2022 (de Moor et al 2013).”